U.S. DNA Manufacturing Market Size Worth USD 11.72 Billion by 2034 | CAGR: 18.14%

The us dna manufacturing market size is expected to reach USD 11.72 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade, By Application, By End Use – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

DNA manufacturing involves the synthetic production of deoxyribonucleic acid (DNA) sequences for use in biotechnology, medicine, and various research applications. Companies synthesize custom DNA strands through chemical processes, enabling advancements in gene therapy, vaccine development, and synthetic biology. DNA manufacturing allows scientists to design and produce genetic molecules for applications such as CRISPR-based gene editing and diagnostic tools. The growing demand for personalized medicine and biopharmaceuticals is driving the expansion of DNA manufacturing, with innovations reducing costs and improving precision. However, ethical concerns, regulatory hurdles, and the complexity of large-scale production pose challenges to the U.S. DNA manufacturing market growth.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/us-dna-manufacturing-market/request-for-sample

The U.S. DNA manufacturing market is growing due to increasing healthcare demands, an aging population, and the rise of chronic diseases. Advances in biotechnology, such as mRNA vaccines and therapeutics, are pushing innovation in the market, while government incentives and private investments are driving market growth. The shift toward personalized medicine and orphan drugs is creating lucrative opportunities for manufacturers.

Top of FormU.S. DNA Manufacturing Market Report Highlights

• In terms of type, the plasmid DNA segment accounted for a major market share in 2024. Pharmaceutical and biotechnology companies drove strong demand for plasmid DNA due to its critical role in cell and gene therapies, DNA vaccines, and viral vector production.
• Based on grade, the GMP grade segment held the largest market share in 2024 due to increasing demand for high-quality synthetic DNA in therapeutic applications, including mRNA vaccines, gene therapies, and cell-based treatments.
• In terms of application, the cell & gene therapy segment dominated the market share in 2024 due to increasing advancements in CRISPR-based gene editing, CAR-T cell therapies, and viral vector production.
• Based on end use, the contract research organizations segment is projected to grow at a robust pace in the coming years, owing to the growing trend of outsourcing in drug discovery and clinical trials.
• A few key market players include AGC Biologics, Bionova Scientific, Catalent, Charles River Laboratories, Danaher, Eurofins Genomics, GenScript, Lonza, Thermo Fisher Scientific, Twist Bioscience, and VGXI, Inc.

Polaris Market Research has segmented the U.S. DNA manufacturing market report on the basis of type, grade, application, and end use:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Plasmid DNA
• Synthetic DNA
  • Gene Synthesis
  • Oligonucleotide Synthesis

By Grade Outlook (Revenue, USD Billion, 2020–2034)

• GMP Grade
• R&D Grade

By Application Outlook (Revenue, USD Billion, 2020–2034)

• Cell & Gene Therapy
• Vaccines
• Oligonucleotide-based drugs
• Others

By End Use Outlook (Revenue, USD Billion, 2020–2034)

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations